Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

IntroductionSomatic inactivation of the TP53 gene in breast tumors is a marker for poor outcome, and breast cancer outcome might also be affected by germ-line variation in the TP53 gene or its regulators. We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival.MethodsWe pooled data from four breast cancer cohorts within the Breast Cancer Association Consortium for which both TP53 R72P and MDM2 SNP309 were genotyped and follow-up was available (n = 3,749). Overall and breast cancer-specific survival analyses were performed using Kaplan-Meier analysis and multivariate Cox's proportional hazards regression models.ResultsSurvival of patients did not differ by carriership of either germ-line variant, R72P (215G>C) or SNP309 (-410G>T) alone. Immunohistochemical p53 staining of the tumor was available for two cohorts (n = 1,109 patients). Survival was worse in patients with p53-positive tumors (n = 301) compared to patients with p53-negative tumors (n = 808); breast cancer-specific survival: HR 1.6 (95% CI 1.2 to 2.1), P = 0.001. Within the patient group with p53-negative tumors, TP53 rare homozygous (CC) carriers had a worse survival than G-allele (GG/GC) carriers; actuarial breast cancer-specific survival 71% versus 80%, P = 0.07; HR 1.8 (1.1 to 3.1), P = 0.03. We also found a differential effect of combinations of the two germ-line variants on overall survival; homozygous carriers of the G-allele in MDM2 had worse survival only within the group of TP53 C-allele carriers; actuarial overall survival (GG versus TT/TG) 64% versus 75%, P = 0.001; HR (GG versus TT) 1.5 (1.1 to 2.0), P = 0.01. We found no evidence for a differential effect of MDM2 SNP309 by p53 protein expression on survival.ConclusionsThe TP53 R72P variant may be an independent predictor for survival of patients with p53-negative tumors. The combined effect of TP53 R72P and MDM2 SNP309 on survival is in line with our a priori biologically-supported hypothesis, that is, the role of enhanced DNA repair function of the TP53 Pro-variant, combined with increased expression of the Mdm2 protein, and thus overall attenuation of the p53 pathway in the tumor cells.

[1]  David J. Hunter,et al.  The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies , 2006, Cancer Causes & Control.

[2]  Genica,et al.  Commonly studied single-nucleotide polymorphisms and breast cancer: Results from the Breast Cancer Association Consortium , 2006 .

[3]  K Holli,et al.  Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.

[4]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Dörk,et al.  Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer , 2001, British Journal of Cancer.

[6]  T. Dörk,et al.  Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. , 2001, Cancer research.

[7]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F. Penault-Llorca,et al.  p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  T. Dörk,et al.  Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. , 2007, Cancer research.

[10]  Yuntao Xie,et al.  p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer , 2005, Clinical Cancer Research.

[11]  T. Crook,et al.  Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo , 2004, Oncogene.

[12]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  L. Holmberg,et al.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. , 1996, Journal of the National Cancer Institute.

[14]  J. Peterse,et al.  Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Ponder,et al.  Effect of germ-line genetic variation on breast cancer survival in a population-based study. , 2002, Cancer research.

[16]  K. Soo,et al.  Evidence for Selective Expression of the p53 Codon 72 Polymorphs: Implications in Cancer Development , 2005, Cancer Epidemiology Biomarkers & Prevention.

[17]  C. Bonaïti‐pellié,et al.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.

[18]  Paul D.P. Pharoah,et al.  Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. , 2007, Journal of the National Cancer Institute.

[19]  J. Overgaard,et al.  LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer , 2006, Acta oncologica.

[20]  Peter Kraft,et al.  Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.

[21]  H. Iwata,et al.  Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients , 2007, Breast Cancer Research.

[22]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[23]  D. Pim,et al.  p53 polymorphic variants at codon 72 exert different effects on cell cycle progression , 2004, International journal of cancer.

[24]  Yuntao Xie,et al.  Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status , 2008, International journal of cancer.

[25]  B. Ponder,et al.  Genetic variants in epigenetic genes and breast cancer risk. , 2006, Carcinogenesis.

[26]  A. Børresen-Dale,et al.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.

[27]  R. Greil,et al.  MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Kadouri,et al.  Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations , 2009, BMC Cancer.

[29]  M. Zvelebil,et al.  iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53 , 2006, Nature Genetics.

[30]  Päivi Heikkilä,et al.  Breast Cancer Patients with p53 Pro72 Homozygous Genotype Have a Poorer Survival , 2005, Clinical Cancer Research.

[31]  G. Prendergast,et al.  The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.

[32]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[33]  B. Gusterson,et al.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.

[34]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[35]  Julie E Goodman,et al.  Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.

[36]  L. J. Veer,et al.  The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes , 2007, European Journal of Human Genetics.

[37]  Miranda Thomas,et al.  Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically , 1999, Molecular and Cellular Biology.

[38]  C. Franceschi,et al.  Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  J. Klijn,et al.  MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling , 2007, Breast Cancer Research and Treatment.

[40]  R. Schneider-Stock,et al.  Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. , 2004, The American journal of pathology.

[41]  Jacqueline Lehmann,et al.  TP53 Status and Response to Chemotherapy in Breast Cancer , 2008, Pathobiology.

[42]  Päivi Heikkilä,et al.  NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer , 2008, Nature Genetics.

[43]  A. Levine,et al.  MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.